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Abstract
Background: Oridonin, a tetracycline diterpenoid compound, has the potential antitumor activities. Here, we
evaluate the antitumor activity and action mechanisms of oridonin in colorectal cancer.
Methods: Effects of oridonin on cell proliferation were determined by using a CCK-8 Kit. Cell cycle distribution was
determined by flow cytometry. Apoptosis was examined by analyzing subdiploid population and terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling assay. Senescent cells were determined by
senescence-associated b-galactosidase activity analysis. Semi-quantitative RT-PCR was used to examine the changes
of mRNA of p16, p21, p27 and c-myc. The concomitant changes of protein expression were analyzed with Western
blot. Expression of AcH3 and AcH4 were examined by immunofluorescence staining and Western blots. Effects of
oridonin on colony formation of SW1116 were examined by Soft Agar assay. The in vivo efficacy of oridonin was
detected using a xenograft colorectal cancer model in nude mice.
Results: Oridonin induced potent growth inhibition, cell cycle arrest, apoptosis, senescence and colony-forming
inhibition in three colorectal cancer cell lines in a dose-dependent manner in vitro. Daily i.p. injection of oridonin
(6.25, 12.5 or 25 mg/kg) for 28 days significantly inhibited the growth of SW1116 s.c. xenografts in BABL/C nude
mice. With western blot and reverse transcription-PCR, we further showed that the antitumor activities of oridonin
correlated with induction of histone (H3 and H4) hyperacetylation, activation of p21, p27 and p16, and suppression
of c-myc expression.
Conclusion: Oridonin possesses potent in vitro and in vivo anti-colorectal cancer activities that correlated with
induction of histone hyperacetylation and regulation of pathways critical for maintaining growth inhibition and cell
cycle arrest. Therefore, oridonin may represent a novel therapeutic option in colorectal cancer treatment.
Background
Colorectal cancer (CRC) is one of the most frequently
diagnosed malignancies in both men and women, with
more than 1,000,000 new cases annually worldwide [1].
Advances in therapies over the past decade have led to
improved outcomes for many patients. Although
curative resection is the major treatment option,
approximately half of all patients eventually develop dis-
tant metastases. Liver metastases (LM) occur in more
than 50% of CRC patients, but curative liver resection is
possible only in 15% of them, resulting in 5-year survival
rates of 30% on average [2-4]. Improving resectability
rates and hopefully patient’s prognosis by adding up
front active chemotherapy and biological agents in
metastatic CRC is a challenging opportunity for both
medical and surgical oncologists [5]. Thus, effective new
cytotoxic chemotherapy is needed for these diseases.
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products; over 22,000 individual compounds of this class
have been described, and the number of defined struc-
tures has doubled every decade since the 1970s [6]. In
plants, terpenoids represent a chemical defense against
environmental stress and provide a repair mechanism
for wounds and injuries. Interestingly, effective ingredi-
ents in several plant-derived medicinal extracts are also
terpenoid compounds of monoterpenoid, sesquiterpe-
noid, diterpenoid, triterpenoid and carotenoid groups.
Experimental study shows that many of them have
strong anti-tumor activity [7]. For example, Tanshinone
IIA, the major active diterpene quinine in the herbal
product from the roots of Salvia miltiorrhiza, is a com-
monly used Chinese plant remedy which seems to have
some activity against breast cancer [8,9]. Celastrol, a
quinone methide triterpenoid, isolated from the Chinese
Thunder of God Vine (Tripterygium wilfordii Hook F.),
as well as triptolide, are currently being investigated in
the search for prevention of tumor cell invasion [10].
Plant-derived terpenoids provide a challenging field to
identify new potent natural anticancer compound for
the therapy of colorectal cancer.
Oridonin, an ent-kaurane diterpenoid isolated from
Rabdosia rubescens, is an important traditional Chinese
herbal remedy. Studies showed that oridonin induced
apoptosis in a variety of cancer cells including those
from prostate, breast, non-small cell lung cancer, acute
leukemia, glioblastoma multiforme and human mela-
noma cells. Cell culture experiments have indicated that
oridonin inhibits cell cycle progression and induces
apoptosis as well as enhance the phagocytosis of apopto-
tic cells by macrophages [11,12]. Oridonin has also
immunosuppressive properties both in vitro and in vivo
[13]. However, mechanisms underlying the antitumor
activity of oridonin and whether oridonin has the anti-
colorectal cancer activity remain largely unknown.
In this report, we found that oridonin could induce
potent growth inhibition, cell cycle arrest, apoptosis and
senescence of colorectal cancer cells in vitro and in
vivo. The antitumor activities of oridonin correlated
with induction of histone (H3 and H4) hyperacetylation,
activation of p21, p27 and p16, and suppression of c-
myc expression.
Methods
Cell Culture and Reagents
The colorectal cancer cell lines SW1116, HT29 and
HCT116 from Shanghai Institutes for Biological
Sciences were incubated in humidified room air contain-
ing 5% CO2 at 37°C and cultured in McCOY’S5 Am e d -
ium (Sigma, USA) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (GIBCO
BRL, Grand Island,NY). Cells were routinely grown in
100 mm plastic tissue culture dishes (Nunc, Roskilde,
Denmark) and harvested with a solution of trypsin-
EDTA when they were in logarithmic phase of growth.
Cells were maintained at these culture conditions for all
experiments. Oridonin (purity > 98%) was purchased
from CHENGDU MUST BIO-TECHNOLOGY CO.
LTD. It was dissolved in DMSO at a stock concentra-
tion of 100 mmol/L and store at -20°C. The stock solu-
tion was further diluted with cell culture medium to
yield final oridonin concentrations.
Cell Proliferation Assay
Cells were seeded into 96-well plates at 2,000 to 3,000
live cells per well and treated with Oridonin (6.25-100
μM) for 3 days. The antiproliferative effect of Oridonin
was assessed using Cell Count Kit-8 (Dojindo Molecular
Technologies, Inc., Gaithersburg, MD).
Cell Cycle Analysis with Flow Cytometry
Cells treated with or without Oridonin (12.5 and 25
μmol/L) were harvested for flow cytometry analysis on
day 1. Cells were fixed and stained with 0.1 mg/mL pro-
pidium iodide for DNA analysis with Becton Dickinson
FACScan (Franklin Lakes, NJ) as described previously
[14].
Detection of Apoptosis
Apoptosis was evaluated with flow cytometry and on
cell smears using the terminal deoxynucleotidyl transfer-
ase-mediated dUTP nick end labeling assay (In situ Cell
Death Detection kit, AP; Boehringer Mannheim GmbH,
Mannheim, Germany). Samples were incubated with 50
μL of reaction mixture in a humidified chamber at 37°C
for 90 minutes as described previously [15]. The percen-
tage of apoptotic cells was determined by counting at
least 1,000 cells from 10 to 20 high-power fields (×200)
under both phase-contrast and fluorescent microscopy.
Cell Senescence Assay
Senescence-associated expression of b-galactosidase
activity [16] was done with a Senescence Detection kit
(BioVision, Mountain View, CA) on fixed cells treated
with or without Oridonin (12.5 and 25 μmol/L). The
development of cytoplasmic blue was detected and
photographed using a Nikon (Nikon Instruments, Inc.,
Lewisville, TX) inverted microscope equipped with a
color CCD camera.
RNA Extraction and Semi-quantitative RT-PCR
Total RNA was extracted from cell cultures using TRI
REAGENT (Molecular Research Center, Inc., OH)
according to the manufacturer’sp r o t o c o l .T h em R N A
levels of the genes analyzed were measured by RT-PCR
amplification. Sequences for mRNAs from the
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Information) were used to design primer pairs for RT-
PCR reactions (Primer Express, Applied Biosystems,
CA). The following specific oligonucleotide primers
were used respectively for p16 (p16-F: 5’-CAC GGC
CGC GGC CCG GGG TC -3’ and p16-R: 5’-GGC CCG
GTG CAG CAC CAC CA -3’ ), p21(p21-F: 5’-AGG
CGC CAT GTC AGA ACC GGC TGG -3’ and p21-R:
5’-GGA AGG TAG AGC TTG GGC AGG C-3’ ), p27
(p27-F: 5’-ATG TCA AAC GTG CGA GTG TCT AAC
-3’ and p27-R: 5’-TTA CGT TTG ACG TCT TCT GAG
GCC A-3’ ), c-myc (c-myc-F: 5’-ATT CTC TGC TCT
CCT CGA -3’ and c-myc-R: 5’-TCT TGG CAG CAG
GAT AGT -3’ ) with GAPDH as internal control
(GAPDH-F: 5’-TCC CAT CAC CAT CTT CCA G-3’
and GAPDH-R:5’-ATG AGT CCT TCC ACG ATA CC-
3’;). PCR cycles were adjusted to have linear amplifica-
tion for all the targets. Each RT-PCR reaction was
repeated at least three times. A semiquantitative analysis
of mRNA levels was carried out by the ‘’GEL DOC UV
SYSTEM’’ (Biorad Company, CA).
Western-blot analysis
Attached cells were collected by scraping them off into a
lysis buffer, and the detached cells in the supernatant
were collected by centrifugation before resuspension in
the lysis buffer. Protein concentration was determined
by the bicinchoninic acid (BCA) method according to
the manufacturer’s (Pierce, Rockford, IL, U.S.A.) instruc-
tions after trichloroacetic acid precipitation. The protein
lysates were mixed with equal volume of Laemmli buffer
(62.5 mM Tris-HCl pH 6.8, 2% SDS, 50 mM DTT, 10%
glycerol, 0.01% bromophenol blue), boiled for 3 min at
100°C, and then resolved by SDS-PAGE on a 10 to 12%
gel using a mini gel apparatus (Bio-Rad). Bromophenol
Blue (0.01%) was added to the samples before an equal
amount of proteins was loaded in each lane for electro-
phoresis and blotting. The PVDF membrane was incu-
bated with a primary antibody against cdc2, cdc25c and
cyclinB (Santa Cruz Biotechnology), p16 (PharMingen,
San Diego, CA, U.S.A.), p21 (PharMingen, San Diego,
CA, U.S.A.), p27 (PharMingen, San Diego, CA, U.S.A.),
c-Myc (N-262; Santa Cruz Biotechnology, Santa Cruz,
CA, U.S.A.), Acetylated histone H3 (AcH3) and H4
(AcH4), phospho-Histone H3 (Ser10) (Upstate Biotech-
nology, Lake Placid, NY), histone 3, histone 4 and
GAPDH (Santa Cruz Biotechnology) for 2 h. Signals
were detected using a horseradish peroxidase-conjugated
secondary antibody and an enhanced chemilumines-
cence detection kit (ECL; Amersham Biosciences, Pitts-
burgh, PA) [17] and were quantitated by an Eagle Eye II
Image System with installed density-analysis software
(Stratagene, La Jolla, CA, U.S.A.).
Immunofluorescent Staining
Cells were fixed with 4% paraformaldehyde in PBS for
15 min at room temperature for anti-acetyl histone H4
(06-598; Upstate Biotechnology) and anti-acetyl histone
H3 (06-599; Upstate Biotechnology) staining. Cells were
permeabilized with 0.2% Triton X-100 (EM Science,
Gibbstown, NJ) in PBS for 10 min at room temperature.
FITC-labeled secondary antibody (F-0382; Sigma) were
applied at the concentration of 1:500. Images were taken
with Nikon E800 scope. Senescence-associated hetero-
chromatin staining was conducted as described [18].
CFE in Soft Agar
Tumor cells were resuspended in DMEM with 0.3% agar
and plated in 24-well plates at 2,000 per well on top of a
0.5 mL precast semisolid 1% agar underlayer following
treatment with Oridonin ( 0, 6.25, 12.5, 25, 50 or
100 μmol/L) for 2 weeks as described previously [15].
The CFE was defined as the percentage of plated cells
that formed colonies relative to an untreated control.
Murine model and oridonin treatment
Five-week-old pathogen-free athymic nude mice were
purchased from Experimental Animal Centre of SIBS.
(Shanghai, PR China). BALB/C nude mice were bred and
maintained in a specific pathogen-free environment.
Mice were allowed free access to mice standard food pel-
lets and tapwater. Twice a week cages were cleaned and
water changed. Temperature was controlled at 21°C ±
2°C. The light was on a 12 hours light-12 hour dark
cycle, with light on at 8 am. Xenograft model in nude
mice was established by subcutaneous inoculation of 1 ×
10
6 SW1116 cells into the right flank. The nude mice
received oridonin treatment (6.25, 12.5 or 25 mg/kg per
day) when tumor was measurable. Caliper measurements
of the longest perpendicular tumor diameters were per-
formed every day to estimate the tumor volume, using
the following formula: 4π/3 × (width/2)
2 × (length/2),
representing the 3-dimensional volume of an ellipse [19].
Animals were killed when their tumors reached 2 cm or
when the mice became moribund. TUNEL assay was per-
formed to detect in situ apoptosis on tissue section using
a DeadEnd Colorimetric TUNEL System (Promega)
according to the manufacturer’s instructions. Senes-
cence-associated expression of b-galactosidase activity
[20] was detected with a Senescence Detection kit (BioVi-
sion, Mountain View, CA) in situ senescence on tissue
section. Animal related experiments were performed
a c c o r d i n gt ot h eG u i d ef o rt h eC a r ea n dU s eo fL a b o r a -
tory Animals (NIH Publications No. 80-23, revised 1996)
and approved by the committee for human treatment of
animals at Shanghai Jiao Tong University School of
Medicine.
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The effects of oridonin on cell proliferation, CFE, cell
cycle arrest, apoptosis, andx e n o g r a f tg r o w t hi nS C I D
mice were analyzed with two-way ANOVA and pre-
sented as the mean ± SD.
Results
Oridonin suppresses colorectal cell proliferation
To investigate the possible effect of oridonin on the pro-
liferation of colorectal cancer cells, three colorectal can-
cer cell lines HCT116, HT29, SW1116 were used. As
shown in Figure 1, oridonin could inhibit proliferation
of the three colorectal cancer cells in a time- and dose-
dependent manner. These tumor cells showed different
sensitivity to the oridonin treatment. It seemed that
HT29 cells are more sensitive to oridonin treatment
than HCT116 and SW1116 cells. The growth of HT29
cells was greatly inhibited by oridonin at 6.25 μM for 24
hours, which become more obvious on day 3. However,
12.5 μM oridonin was needed to obtain 50% inhibition
in HCT1116 and SW1116 cells on day 3. At 25 μM,
growth of all three colorectal cancer cell lines was com-
pletely inhibited.
Oridonin induces cell cycle arrest and augments
apoptosis
We next examined the effects of oridonin on cell cycle
distribution and apoptosis. HCT116 and SW1116 cells
were treated with oridonin at low dose (12.5 μMf o r
HCT116 or 25 μM for SW1116) or at higher dose (25
μM for HCT116 or 50 μM for SW1116) for 24 hours.
Low dose oridonin causes obvious G2/M arrest in
HCT116 and SW1116 cells. As shown in Figure 2A and
2B, the population of G2/M cells increased from 23.5%
and 18.2% to 44.1% and 39.6%, respectively in HCT116
and SW1116 cells. Further, the G2/M related protein
Figure 1 Oridonin inhibits cell proliferation of colorectal cancer cells. (A) Chemical structure of oridonin. (B), (C) and (D) HCT116, HT29 and
SW1116 cells were treated with 0, 6.25, 12.5, 25, 50 100 μM oridonin for 1, 2 and 3 days. Effects of oridonin on cell proliferation were
determined by using a CCK-8 Kit. Error bars represent SD of experiments.
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were detected in HCT116 and SW1116 cells (Figure 2C
and 2E). Oridonin treatment for 12, 24 h causes down-
regulation of all these proteins, indicating that oridonin
induces G2 arrest in these cells.
While at higher concentration (25 μMf o rH C T 1 1 6o r
50 μM for SW1116), a marked increase of subdiploid
peak was observed, indicating the increase of apoptotic
cells. This apoptosis inducing effect of oridonin was
further confirmed by the terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling assay (Fig-
ure 2D and 2F). These results suggested cell cycle arrest
and apoptosis induction involved in oridonin induced
cell proliferation inhibition.
Oridonin induces cellular senescence
Cellular senescence has been identified as one of the
mechanisms mediating the anticancer effects of che-
motherapies [16]. One of the morphologic changes that
were frequently observed in the oridonin-treated cells is
the flattening of the adherent cells with increased granu-
larity, which is a typical morphologic change associated
with cellular senescence (Figure 3A and 3C). By
examining senescence-associated expression of b-galac-
tosidase activity, we confirmed that cellular senescence
was indeed induced in those flattened HCT116 and
SW1116 cells treated by oridonin (12.5 or 25 μM) for
three days (Figure 3B and 3D), indicating that senes-
cence inducing also contribute to the proliferation inhi-
bition effect of oridonin.
Oridonin activates p21, p16 and p27 expression and
down-regulates the expression of oncogene c-myc
To perform detailed temporal analysis of gene expres-
sion alteration, SW1116 cells were treated with 25 μM
oridonin for 0, 24, 48 and 72 hours. Then, the mRNA
and protein levels of p16, p21, p27 were examined. As
shown in Figure 4A and 4C, after treated oridonin for
24 hours, the mRNA and protein level of p21 but not
p16 and p27 were significantly increased. Treatment
with oridonin for 48 and 72 hours resulted in increase
of the p16, p21 and p27. A series of studies have docu-
mented that c-myc regulates a wide range of genes
involved in cell proliferation, differentiation, and apopto-
sis [21]. We also detected the expression of c-myc in
oridonin treated SW1116 cells. Treatment with oridonin
Figure 2 Oridonin induces cell cycle arrest and apoptosis. HCT116 and SW1116 cells were treated with 0, 12.5, 25 or 50 μM Oridonin for 24
hours. Cell cycle distribution was determined by flow cytometry and the representative graphs are shown in (A) and (B). Apoptosis was
examined by analyzing subdiploid population (A and B, black arrow) and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
assay (D and F), in which at least 1,000 cells from randomly selected high-power fields were counted. Symbol * represents P < 0.05 compared
with control group. The indicated proteins were detected by western blot (C and E).
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Page 5 of 11Figure 3 Oridonin induces cellular senescence. HCT116 and SW1116 cells were treated with 0, 12.5 or 25 μM oridonin for 72 hours.
Morphology of control cells and oridonin-treated cells were examined by phase-contrast microscopy (A and C) (×200). Senescent cells were
determined by senescence-associated b-galactosidase activity analysis (B and D) (×200).
Figure 4 Oridonin regulates the expression of p21, p16, p27 and c-myc in vitro. SW1116 cells were treated with 25 μM Oridonin for 0, 24,
48 and 72 hours. Semi-quantitative RT-PCR was used to examine the changes of mRNA of p16, p21, p27 and c-myc (A). (B) The graph shows
densitometric analyses of the p16, p21, p27 or c-myc/GAPDH the ratios from (A). The concomitant changes of protein expression were analyzed
with Western blot (C). (D) The graph shows densitometric analysis of the p16, p21, p27 or c-myc relative to GAPDH. Symbol * represents P <
0.05 compared with control group.
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tion and c-myc protein levels as early as 24 hours.
These data suggested that suppression of c-myc and up-
regulation of p16, p21 and p27 correlated with oridonin
responsiveness of colorectal cancer cells.
Oridonin induces global changes in chromatin structure
Cellular senescence is known to be associated with
changes in chromatin structure [18,22]. Therefore, we
examined global chromatin modifications associated with
cellular senescence in SW1116 cell lines treated with ori-
donin (25 μM) for 3 days in vitro.A ss h o w ni nF i g u r e
5A, after 72 h of oridonin treatment, heterochromatin
formation were observed with DAPI staining, and a
marked global increase of total acetylation of histone H3
and histone H4 were detected by immunofluorescence.
Time course analysis showed that protein levels of acety-
lation of histone H3 and histone H4 gradually increased,
especially for histone H4 (Figure 5B and 5C). Hence, ori-
donin treatment resulted in global changes of histone
modifications that have been associated with cellular
senescence.
Oridonin Suppresses CFE
To examine the suppressive effects of oridonin on CFE,
SW1116 cells were treated with 0, 6.25, 12.5, 25, 50, 100
μM oridonin for 14 days. Our results showed that orido-
nin exerted dose-dependant suppression of CFE in
SW1116 cells (P < 0.01; Figure 6A). Treatment with
6.25 μM oridonin for 2 week causes over 50% inhibition
of CFE. With the increase in drug concentration, more
significant suppressive effects were observed. At higher
Figure 5 Induction of hyperacetylated histone H3 (AcH3) and H4 (AcH4) during the treatment with oridonin. SW1116 cells were treated
with 25 μM oridonin for 72 hours. (A) Heterochromatin formation was shown by DAPI staining. Distribution of AcH3 and AcH4 were examined
by immunofluorescence staining with the indicated antibodies (×200). (B) Protein levels of AcH3 and AcH4 were detected by Western blots with
the indicated antibodies. H3 , H4 and GAPDH were used as loading control. (C) The graph shows densitometric analysis of the expression of
AcH3 and AcH4 relative to GAPDH. Symbol * represents P < 0.05 compared with control group.
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was completely inhibited (Figure 6A).
Oridonin Suppresses the Growth of SW1116 Xenografts
in BALB/C nude mice
We next further assessed the in vivo anti-colorectal can-
cer effects of oridonin. BALB/C nude mice xenografts
were treated with oridonin by daily i.p injection at 6.25
or 12.5 or 25 mg/kg for up to 28 days. Such treatment
resulted in significant suppression of xenograft growth,
compared with the PBS or DMSO (1% in PBS) treated
group (P < 0.05; Figure 6B and 6C). In the low-dose
(6.25 mg/kg) group, significant tumor growth inhibition
effect was observed until 21 days, while in the middle
dose (12.5 mg/kg) group, significant tumor growth inhi-
bition effect was observed on day 14. More interesting,
the high dose (25 mg/kg) administration almost comple-
tely inhibited tumor growth at the onset phase. It is
worth noting that no obvious changes in body weight
were observed in the oridonin treated groups, compared
with the PBS or DMSO (1% in PBS) treated groups (Fig-
ure 6D). In H & E stained tumor section, sparse tumor
cells and areas of necrosis foci can be seen in oridonin
treated mice, while massive tumor cells were observed
in PBS or DMSO (1% in PBS) treated mice (Figure 7A).
TUNEL assay (Figure 7B) and Senescence-associated-b-
galactosidase (SA-b-Gal) staining (Figure 7C) were also
performed to detect the degree of apoptosis and senes-
cence. The results showed that oridonin induces apopto-
sis and senescence of colorectal cells in vivo in a dose
dependent manner.
Discussion
Chemotherapy remains the primary treatment for sys-
temic malignancies. It is now clear that drug-induced
damage is not invariably lethal, but can instead initiate a
series of post-damage responses including apoptosis,
mitotic catastrophe, and cellular senescence [23,24].
Figure 6 Oridonin inhibits colony formation of SW1116 in vitro and tumor growth in vivo. SW1116 cells were treated with 0, 6.25, 12.5,
25, 50, 100 μM oridonin for 14 days. (A) The CFE was defined as the percentage of plated cells that formed colonies relative to an untreated
control (untreated cells = 100%). The means ± standard deviations of six independent experiments per oridonin concentration are shown. The
symbol * represents P < 0.05 compared with control group. SW1116 cells (1 × 10
7 cells in 100 μl of PBS) were subcutaneously injected into the
right flank of BALB/c nude mice. The mice were then administered intraperitoneally with 0.2 ml of PBS or DMSO (1% in PBS) or Oridonin (6.25,
12.5 and 25 mg/kg respectively) daily when tumors reached a volume of 50-100 mm
3. (B) Tumor dimension was periodically measured using
calipers over a 4-week period. Each point represents average volume calculated from ten mice. (C) One day after the last treatment, tumors were
excised from the animals, and tumor weight was measured. The data are representative of three independent experiments. Symbol * represents
P < 0.05 compared with control group. (D) Changes in body weight of mice treated with PBS or DMSO (1% in PBS) or oridonin.
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also influence treatment sensitivity. In the current study,
we showed that the potent anti-cancer activities of orido-
nin in colorectal cancer are correlated with induction of
apoptosis, cell-cycle arrest and cellular senescence.
Oridonin treatment resulted in significant growth
arrest in colorectal cancer cells and this in vitro effect
was time and concentration dependent. This finding is
in agreement with our previous results with oridonin in
acute promyelocytic leukemia cells and others [14].
More importantly, we further showed that oridonin pos-
sesses strong inhibitory activities on tumorigenicity of
colorectal cancer cells. Oridonin at 6.25 μM could inhi-
bit the colony-forming by 50%. With the increase in
drug concentration, the formation of colony was almost
completely inhibited. In consistent with these results in
vitro, treatment with 6.25 mg/kg oridonin in SW1116
xenografts BALB/C nude mice for 4 weeks was able to
significantly decrease the growth of xenografts. These
results provided strong evidence to support the notion
that oridonin has strong activity against colorectal
cancer.
A p o p t o s i si saw e l l - c h a r a c terized post-damage pro-
gram and diverse anticancer agents can induce apoptosis
through common pathways [24]. It has been reported
previously that the antitumor effect of oridonin was due
to its apoptosis induction activity [14,25-28]. In agree-
ment with these reports, our data showed oridonin
could induce apoptosis of colorectal cancer cells in vitro
and in vivo. In addition to apoptosis induction, we
found that oridonin could induce senescence of colorec-
tal cancer cells. In fibroblasts and epithelial cells, senes-
cence is controlled by the p53 and Rb tumor suppressor
pathways, although the contribution of each pathway to
the program depends on species and cell type [20].
Here, oridonin-induced arrest was accompanied by sub-
stantial increases in p21, p16 (an Rb regulator linked
exclusively to senescence) and SA-b-gal activity. It is inter-
esting to note that oridonin-induced senescence associated
with G2 arrest. In most cases, the senescence is associated
with G1/G0 arrest. However, many reports also showed
that G2/M arrest is associated with senescence [29-32].
For example, some drugs including DNA damage agent
Adriamycin, DNA methylating agent Temozolomide,
HDAC inhibitor sodium butyrate could induce G2/M
arrest and senescence-like phenotype via p21 induction.
Similar to these results, oridonin could also up-regulate
the expression of p21, p27 and p16, which may contribute
to the observed senescent phenotype.
The expression of cyclin-dependent kinase inhibitor
p21 and p27 has been implicated in chemotherapy-
induced cell cycle arrest in numerous human cancers
Figure 7 Oridonin inhibits tumor growth in nude mice through induction apoptosis and senescence. The mice were administered
intraperitoneally with 0.2 ml of PBS or DMSO (1% in PBS) or indicated dose of oridonin for 28 days, then the tumors were excised for
pathological examination. (A). Tumor section from PBS or DMSO (1% in PBS) or oridonin treated mice were stained with hematoxylin-eosin (HE)
(×200). (B). Apoptotic colorectal cells were assessed by fluorescent TUNEL assay (×100). (C). Senescent colorectal cells were examined by
Senescence-associated-b-galactosidase (SA-b-Gal) staining (×200).
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able of activating p21 and p27 gene in colorectal cancer
cells. Overexpression of c-myc had been frequently
detected in colorectal cancer and is associated with
shorter survival and tumor anaplasia [35-37]. C-myc has
also been reported to promote cell cycle reentry and
proliferation through repression of p21 and p27 expres-
sion [38]. Therefore, the suppression of c-myc expres-
sion by oridonin may render substantial therapeutic
benefits in colorectal cancer patients by inhibiting the
driving activities of c-myc in cell proliferation and cell
cycle progression. In line with previous reports, our data
showed oridonin- induced p21 and p27 and down-regu-
lated c-myc in vitro.
Epigenetic changes are tightly related to neoplastic
transformation in colorectal cancers. Histone modifica-
tions, recently recognized as a ‘histone code’ that affects
chromatin structure and gene expression also play an
important role in the establishment of gene silencing
during tumorigenesis. Alterations in histone modifica-
tions appear to be primary mediators of epigenetic
inheritance in cancer cells [39-41]. The potential reversi-
bility of epigenetic states in the tumor cell is an attrac-
tive target for cancer therapy [42]. Our data showed
oridonin induced histone (H3 and H4) hyperacetylation
in vitro. We also found that the levels of accumulated
AcH3 and AcH4 correlated with the degree of in vitro
growth suppression in the oridonin-sensitive colorectal
cancer cell lines, suggesting that the anti-colorectal can-
cer effects of oridonin were at least partly mediated
through histone H3 and H4 hyperacetylation.
Conclusions
In summary, we showed that oridonin possesses potent
in vitro and in vivo anti-colorectal cancer activities by
suppressing cell proliferation, promoting apoptosis,
inducing cell cycle arrest and cellular senescence.
These results may lay the groundwork for further stu-
dies using specific genetically engineered models to
establish the causal relationship between oridonin anti-
tumor activity and specific genetic pathways and to
identify molecular markers that will predict drug
responsiveness and guide the development of future
clinical therapies.
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